NCT06972056 - Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study | Biotech Hunter

Enrollment

1,335

Participants

Timeline

Start Date

July 9, 2025

Primary Completion Date

March 1, 2029

Study Completion Date

December 1, 2029

Conditions

Migraine

Interventions

DRUG

Atogepant 60 mg

Atogepant at a dose up to 60 mg daily.

DRUG

Propranolol 160 mg

Daily propranolol up to 80 mg twice daily.

DRUG

Topiramate 100 mg

Daily topiramate, up to 50 mg twice daily

Trial Locations (7)

NOT_YET_RECRUITING

Mayo Clinic Florida, Jacksonville

RECRUITING

Apple Med Research, Miami

NOT_YET_RECRUITING

Mayo Clinic, Rochester

RECRUITING

Mayo Clinic Arizona, Phoenix

RECRUITING

Northern Arizona Healthcare, Flagstaff

NOT_YET_RECRUITING

USC Keck, Los Angeles

RECRUITING

Clinical Research Institute, Los Angeles